Equities research analysts at Leerink Partnrs dropped their Q4 2024 earnings per share estimates for United Therapeutics in a ...
Leerink Partnrs dropped their FY2024 earnings per share estimates for shares of United Therapeutics in a research report ...
United Therapeutics (UTHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in ...
Zacks.com on MSN1d
Ardelyx (ARDX) Earnings Expected to Grow: Should You Buy?The market expects Ardelyx (ARDX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...
We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...
Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), a $15.77 billion market cap company with an "Excellent" financial health rating according to InvestingPro, executed a ...
About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...
A biotechnology company in Research Triangle Park has taken a major step to develop a new option for patients in need of a ...
The settlement agreement resolves all outstanding patent litigation relating to AUVELITY.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback